Cipla Targets $1-b India Sales Through New Drugs, Tie-ups
Cipla, ranked third in the $17-billion Indian
pharmaceutical market after Sun Pharma and Abbott, is setting its eyes on
reaching a billion dollar sales mark, backed by new drug launches from its own
research labs and a slew of partnerships with multinational and Indian drug
firms.
On a moving annual total basis, Cipla's India
sales rose 8.6% to `5,033 crore in August, according to the AIOCD PharmaTrac
data. Its market share stood at 4.9% compared to Sun Pharma's 8.7% and Abbott's
6.23% during the same period.
Umang Vohra, the newly designated managing director of Cipla,
told ET Now that he hoped the India sales to cross a billion dollar “relatively
soon“.
Cipla has stepped up launch plans in areas
like respiratory, dermatology, cardiovascular and urology, which will help
speed up its India growth. Also, several Indian and multinational drug makers
have evinced interest in partnering with Cipla, said Vohra, who took over from
Subhanu Saxena this month.
He said both Indian and multinational drug
makers are approaching Cipla to partner for the India launch of several
products.
“And
so, India will continue to launch 3% to 4% of our sales year-on-year and our
volume growth will continue to be upward of 8% to 10%. We are looking at our
India growth at 13% to 15% range, over a longer time period,” he said.
In 2014, Cipla partnered with Merck to sell
its HIV drug brand, Isentress, under a different brand name.The same year,
Cipla signed a licensing agreement with Gilead, alongside a bunch of other
Indian companies, to market its Hepatitis C drug sofosbuvir.
An analyst said the plan to reach a billion dollar
in India sales in the foreseeable future seems ambitious and may be “uphill“,
unless the company signs deals of a substantial size, either for brands or
companies or enter into strategic joint ventures with other drug makers.
Last year, Cipla changed its reporting
structure for sales in the Indian market. It started booking revenues on actual
sales against the earlier process, which booked sales at the stage of
despatching the product.
Comments
Post a Comment